Archives
-
Exo1 and the Next Generation of Exocytic Research
2026-08-31
Exo1 provides a mechanistically differentiated way to interrogate Golgi–ER traffic, ARF1 behavior, and exocytic output. This thought-leadership perspective connects acute membrane trafficking inhibition with tumor extracellular vesicle biology while separating experimentally useful hypotheses from clinically validated evidence.
-
U0126-EtOH for Spatial ERK Assays
2026-08-30
U0126-EtOH is a selective MEK1/2 inhibitor for testing how ERK activity encodes cell position. This guide connects axolotl limb-regeneration biology with rigorous spatial, neuronal, and inflammatory assay design.
-
IPA-3: From Pak1 Mechanism to Translational Insight
2026-08-29
IPA-3 offers a mechanistically differentiated way to interrogate group I Pak signaling. This thought-leadership analysis connects its non-ATP-competitive mode of action with kinase assay design, cancer biology research, neuroinflammation, and the important boundary conditions revealed by an antiviral entry study.
-
PPARα–TF Signaling in Pulmonary LELC
2026-08-28
A 2025 reference preprint combines DIA proteomics, untargeted metabolomics, functional experiments, and a patient-derived xenograft model to define a linoleic acid–PPARα–tissue factor axis in primary pulmonary lymphoepithelioma-like carcinoma. The findings connect lipid metabolism regulation with tumor immune remodeling and identify tissue factor as a potentially actionable node, while requiring further validation in larger and independent cohorts.
-
FITC-Concanavalin A (ConA) Conjugate Guide
2026-08-28
FITC-Concanavalin A (ConA) Conjugate provides direct fluorescent detection of α-D-glucose and α-D-mannose residues on glycoproteins and glycolipids in cell and tissue samples. It is suited to immunofluorescence staining, flow cytometry carbohydrate probe workflows, and glycobiology research, but not to non-carbohydrate targets or use outside the stated storage and stability conditions.
-
YAP–TEAD Links PPARα to Liver Growth and Regeneration
2026-08-27
The reference study identifies YAP–TEAD signaling as a functional mediator of PPARα-induced hepatomegaly and liver regeneration in mice. By combining pharmacological activation with hepatocyte-specific PPARα and YAP loss-of-function models, the work connects a metabolic nuclear receptor to a tissue-growth pathway and provides a mechanistic framework for interpreting WY-14643 responses in liver research.
-
FGFR2 Fusion Targeting in Intrahepatic Cholangiocarcinoma
2026-08-27
The reference study develops a cholesterol-conjugated DNA/RNA heteroduplex oligonucleotide that selectively suppresses the FGFR2-AHCYL1 fusion in intrahepatic cholangiocarcinoma. Its findings also identify an EGFR–STAT1–ASNS axis that sustains asparagine production and tumor-cell survival, providing a mechanistic rationale for combining FGFR2-directed therapy with asparagine depletion.
-
(S)-Mephenytoin for CYP2C19 Assays
2026-08-26
Use (S)-Mephenytoin as a practical CYP2C19 substrate benchmark across recombinant enzymes, microsomes, and emerging human intestinal organoid models. Its defined solubility, storage, and kinetic information supports assay development while revealing where organoid maturity, matrix effects, and CYP2C19-specific validation still matter.
-
CDC42 Polarity Controls Intestinal Stem Cell Fate
2026-08-26
Zhang and colleagues show that CDC42-dependent epithelial polarity is an active regulator of the intestinal stem cell-to-transit amplifying cell transition, rather than merely a structural feature. Their mouse genetics and rescue experiments identify a YAP/TAZ–Ereg–EGFR–mTOR cascade that links polarity disruption to crypt hyperproliferation independently of canonical Wnt signaling.
-
Praeruptorin A: Workflows for Inflammation & Cancer
2026-08-25
Praeruptorin A supports mechanism-led workflows spanning DMT1-associated ferroptosis, intestinal barrier protection, doxorubicin-related cardiac injury, and ERK1/2–MMP1 metastatic behavior. This guide converts those signals into practical dosing, assay-selection, combination, and troubleshooting strategies for preclinical research.
-
Reversine: Aurora Kinase Inhibitor for Mitotic Research
2026-08-25
Reversine is an Aurora kinase inhibitor used to investigate mitotic regulation, cancer cell proliferation inhibition, and apoptosis induction in cancer cells. Product data report activity against Aurora kinases A, B, and C, while peer-reviewed work supports its use in cell-fate and high-content cellular research.
-
Dicloxacillin Activity Against Intracellular S. aureus
2026-08-24
The reference study compared dicloxacillin activity against intracellular and extracellular Staphylococcus aureus using THP-1 cells and a modified mouse peritonitis model. Its central finding was that free-drug exposure above the MIC, rather than peak concentration or total exposure alone, best predicted efficacy in both compartments, providing a useful PK/PD framework for MSSA infection research.
-
JNJ-26854165 (Serdemetan) Assay Workflows
2026-08-24
Build more informative HDM2–p53 experiments with JNJ-26854165 (Serdemetan), separating growth arrest from true cell killing. This workflow also supports genotype-aware apoptosis studies, migration assays, and radiation-response experiments rather than relying on a single viability endpoint.
-
L1023 Anti-Cancer Compound Library Workflow
2026-08-23
Turn a 1,164-compound collection into a practical discovery engine for pathway profiling, phenotypic screening, and mechanism-focused cancer research. This workflow pairs broad chemical coverage with orthogonal validation strategies inspired by the DHHC9–STRN4–YAP metastasis study.
-
Y-27632 in NIID iPSC Assay Design
2026-08-22
Explore how Y-27632, a selective ROCK inhibitor, can be used as a mechanistic perturbation tool in patient-derived NIID iPSC research. This article connects ROCK-dependent cytoskeletal phenotypes with the NOTCH2NLC repeat-expansion model while defining practical assay limits.